Status:
RECRUITING
Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF
Lead Sponsor:
University Medical Center Goettingen
Conditions:
Heart Failure With Preserved Ejection Fraction
Cardiovascular Morbidity
Eligibility:
All Genders
18+ years
Brief Summary
Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investig...
Eligibility Criteria
Inclusion
- One or more of the following criteria:
- Age \> 60 years
- Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs)
- Diabetes mellitus Type I or II
- Atrial fibrillation
- Chronic kidney disease (GFR \< 60 ml/min/1,73 m2 or urine albumin ≥ 30mg/24h or ACR ≥ 30 mg/g)
- BMI ≥ 30 kg/m2
- NYHA ≥ II
- E/e' \> 8
Exclusion
- Left ventricular ejection fraction \< 50 %
- Significant valve disease (Grade III or higher)
- History of interventional or surgical valve repair
- Regional wall motion abnormalities
- Respiratory diseases as a known cause for dyspnea
- Atrial flutter or fibrillation during examination
- Hypertrophic/restrictive/arrhythmogenic/dilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy
- History of heart transplantation
Key Trial Info
Start Date :
February 23 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2028
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06208007
Start Date
February 23 2024
End Date
January 1 2028
Last Update
May 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsmedizin Göttingen
Göttingen, Lower Saxony, Germany, 37075